Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic.

Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study. Br J Cancer (2011) 0.96

The effect of demographic and clinical factors on the relationship between BMI and PSA levels. Prostate (2011) 0.95

Obesity and future prostate cancer risk among men after an initial benign biopsy of the prostate. Cancer Epidemiol Biomarkers Prev (2013) 0.83

Association of obesity and diabetes with serum prostate-specific antigen levels in Japanese males. Nagoya J Med Sci (2012) 0.82

Body mass index and prostate cancer severity: do obese men harbor more aggressive disease on prostate biopsy? Urology (2013) 0.81

Health-and disease-related biomarkers in aging research. Res Gerontol Nurs (2009) 0.79

The likelihood of having a serum PSA level of ≥2.5 or ≥4.0 ng ml(-1) according to obesity in a screened Korean population. Asian J Androl (2013) 0.76

Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14

Autonomic nerve development contributes to prostate cancer progression. Science (2013) 6.11

Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst (2009) 4.87

Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol (2008) 4.75

Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24

Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25

A framework for the identification of men at increased risk for prostate cancer. J Urol (2009) 3.07

The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst (2008) 2.46

Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol (2013) 2.46

Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology (2010) 2.45

Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol (2007) 2.42

NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40

Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36

The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29

Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev (2006) 2.28

Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. J Urol (2009) 2.23

Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database. Urology (2009) 2.23

Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75. Urology (2009) 2.09

Association between exercise and primary incidence of prostate cancer: does race matter? Cancer (2013) 2.07

High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06

Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol (2012) 2.05

Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. J Urol (2010) 2.05

Obesity and prostate cancer: weighing the evidence. Eur Urol (2012) 2.01

Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev (2008) 1.99

Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer (2006) 1.97

The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol (2009) 1.97

Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer (2007) 1.96

Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95

Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer. J Urol (2010) 1.94

The role of genetic markers in the management of prostate cancer. Eur Urol (2012) 1.88

NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (2009) 1.86

Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol (2009) 1.85

The correlation between metabolic syndrome and prostatic diseases. Eur Urol (2011) 1.83

Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol (2012) 1.81

Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database. Cancer (2013) 1.78

Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database. Prostate (2012) 1.76

Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol (2009) 1.75

The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol (2010) 1.73

Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer (2013) 1.66

The relationship between nutrition and prostate cancer: is more always better? Eur Urol (2012) 1.66

Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol (2012) 1.64

Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev (2012) 1.63

Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol (2007) 1.63

Timing of curative treatment for prostate cancer: a systematic review. Eur Urol (2013) 1.63

Understanding variation in primary prostate cancer treatment within the Veterans Health Administration. Urology (2012) 1.62

Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer (2010) 1.59

Factors predicting prostatic biopsy Gleason sum under grading. J Urol (2009) 1.59

Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer (2010) 1.59

Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int (2014) 1.58

Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int (2011) 1.54

Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance. J Urol (2013) 1.54

The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer. Cancer (2014) 1.51

The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy. World J Urol (2012) 1.51

Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res (2006) 1.50

Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group. Urology (2013) 1.48

A systematic review of the volume-outcome relationship for radical prostatectomy. Eur Urol (2013) 1.48

Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol (2002) 1.48

Quality of life, pain and return to normal activities following laparoscopic donor nephrectomy versus open mini-incision donor nephrectomy. J Urol (2003) 1.47

Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. J Urol (2010) 1.45

Predicting occult multifocality of renal cell carcinoma. Eur Urol (2010) 1.45

The effect of dietary sodium and fructose intake on urine and serum parameters of stone formation in a pediatric mouse model: a pilot study. J Urol (2013) 1.44

Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy. Urology (2009) 1.44

Greater percent-free testosterone is associated with high-grade prostate cancer in men undergoing prostate biopsy. Urology (2012) 1.43

Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. Int J Urol (2015) 1.42

Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2011) 1.42

Obesity and prostate cancer: importance of race and stage of disease. J Urol (2007) 1.41

Association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy. Int J Urol (2012) 1.40

Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases. Int J Urol (2010) 1.40

Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH database. Urology (2012) 1.39

Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol (2011) 1.36

High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int (2009) 1.36

Rising PSA in nonmetastatic prostate cancer. Oncology (Williston Park) (2007) 1.35

Changing concepts in the management of renal oncocytoma. Urology (2002) 1.31

Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol (2002) 1.31

Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol (2004) 1.30

Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml. J Urol (2006) 1.29

Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004. Cancer Causes Control (2010) 1.29

Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy. J Urol (2009) 1.28

Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature. Eur Urol (2010) 1.28

A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer. Nutr Res (2011) 1.24

Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy. Cancer Prev Res (Phila) (2011) 1.23

Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database. Urology (2007) 1.22

Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: results from the SEARCH database. J Urol (2008) 1.21

Hidden barriers between knowledge and behavior: the North Carolina prostate cancer screening and treatment experience. Cancer (2007) 1.17

Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease. Eur J Nucl Med Mol Imaging (2002) 1.17

Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer. J Appl Physiol (1985) (2009) 1.17

Association of cigarette smoking with interval to biochemical recurrence after radical prostatectomy: results from the SEARCH database. Urology (2010) 1.16

Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. J Urol (2006) 1.15

Changing nature of high risk patients undergoing radical prostatectomy. J Urol (2007) 1.15

Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer (2006) 1.14

The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prev Res (Phila) (2009) 1.13

Race, healthcare access and physician trust among prostate cancer patients. Cancer Causes Control (2009) 1.12

Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer (2009) 1.11

Testicular cancer. J Natl Compr Canc Netw (2012) 1.11

Complications after percutaneous radiofrequency ablation of renal tumors. Urology (2005) 1.10

Commentary on "Integrative clinical genomics of advanced prostate cancer". Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.Cell. 21 May 2015;161(5):1215-1228. Urol Oncol (2017) 1.10

Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. J Appl Physiol (1985) (2012) 1.08